PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Pomalidomide

Drugs in development · updated 30 October 2026

Pomalidomide: clinical trials and development status

Other names and codes: Imnovid, Pomalyst

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 5 August 2013

As of 30 October 2026 Pomalidomide is in 101 active clinical trials (recruiting or ongoing, phases I–III) for 28 diseases. The most advanced phase is III.

101Active trials
IIIMost advanced phase
28Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pomalidomide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Multiple myelomaIII78NCT05519085
NeoplasmIII6NCT07728188
Plasma cell neoplasmIII4NCT06152575
Immunoglobulin Light-chain AmyloidosisII4NCT04270175
Diffuse large B-cell lymphomaII3NCT07523737
Acute myeloid leukemiaII2NCT04802161
Non-Hodgkin lymphomaI–II2NCT04068597
Residual neoplasmII2NCT07748689
Blood protein diseaseI–II1NCT05581875
Chromosome 17 deletionII1NCT04124497
Chronic myelomonocytic leukemiaII1NCT04802161
Corneal diseaseI–II1NCT05581875
Hematologic DiseasesI–II1NCT05581875
Hematologic neoplasmI–II1NCT04068597
Interdigitating dendritic cell sarcomaII1NCT07749365
Myelodysplastic SyndromesII1NCT04802161
Myeloproliferative disordersII1NCT04802161
ParaproteinemiaI–II1NCT05581875
Peripheral T-cell lymphomaI–II1NCT04068597
Proteostasis DeficienciesI–II1NCT05451771
Acquired Immunodeficiency SyndromeI2NCT04902443
B-cell lymphomaI2NCT07532525
Burkitt lymphomaI2NCT07532525
Kaposi's sarcomaI2NCT04902443
Epstein–Barr virus infectionI1NCT05389423
Multi-centric Castleman's DiseaseI1NCT02659930
Plasmablastic lymphomaI1NCT05389423
Smoldering Multiple MyelomaI1NCT06768489

Everything on Pomalidomide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch